Europe Pharmaceuticals and Healthcare Report Q2 2017
|出版日期||內容資訊||英文 47 Pages
|歐洲的醫藥品、醫療產業 (季度更新報告) Europe Pharmaceuticals and Healthcare Report Q2 2017|
|出版日期: 2017年04月26日||內容資訊: 英文 47 Pages||
本報告提供歐洲各國的製藥產業及醫療產業相關分析，地區整體產業規模的實際成果值、預測值 (過去5年、今後10年份) 估計，產業的課題 (風險) 和未來性的商機 (利潤) 相關評估，域內各地區的詳細趨勢，主要企業簡介等資訊彙整，為您概述為以下內容
BMI View:While the ageing of populations will increase the prevalence of chronic diseases across Europe, driving up demand for medicines, the outlook for the emerging and developed Europe sub-regions is divergent. In emerging European markets, the heavy focus on expansion of healthcare access will drive its outperformance. Cost containment will be prominent throughout the region although this will manifest in different forms; Western European markets will be hit by stricter reimbursement levels and pricing control while generic substitution policies will become more prominent in emerging Europe.
Despite the political risks to the eurozone (see below), economic growth momentum is improving, aided by a more supportive global growth backdrop. Our growth forecast for the bloc has been revised up this year to 1.6%. That said, structural factors including large debt loads and underlying eurozone imbalances continue to weigh on growth potential. Economic growth in Central and Eastern Europe will rebound from the drop in EU structural funding in 2016, averaging 3.0% in 2017.